Taming the cytokine storm: small molecule inhibitors targeting IL-6/IL-6α receptor
- PMID: 38366102
- DOI: 10.1007/s11030-023-10805-5
Taming the cytokine storm: small molecule inhibitors targeting IL-6/IL-6α receptor
Abstract
Given the increasing effectiveness of immune-based therapies, management of their associated toxicities is of utmost importance. Cytokine release syndrome (CRS), characterized by elevated levels of cytokine, poses a significant challenge following the administration of antibodies and CAR-T cell therapies. CRS also contributes to multiple organ dysfunction in severe viral infections, notably in COVID-19. Given the pivotal role of IL-6 cytokine in initiating CRS, it has been considered a most potential therapeutic target to mitigate hyperactivated immune responses. While monoclonal antibodies of IL-6 show promise in mitigating cytokine storm, concerns about immunotoxicity persist, and small molecule IL-6 antagonists remain unavailable. The present study employed sophisticated computational techniques to identify potential hit compounds as IL-6 inhibitors, with the aim of inhibiting IL-6/IL-6R protein-protein interactions. Through ligand-based pharmacophore mapping and shape similarity in combination with docking-based screening, we identified nine hit compounds with diverse chemical scaffolds as potential binders of IL-6. Further, the MD simulation of 300 ns of five virtual hits in a complex with IL-6 was employed to study the dynamic behavior. To provide a more precise prediction, binding free energy was also estimated. The identified compounds persistently interacted with the residues lining the binding site of the IL-6 protein. These compounds displayed low binding energy during MMPBSA calculations, substantiating their strong association with IL-6. This study suggests promising scaffolds as potential inhibitors of IL-6/IL-6R protein-protein interactions and provides direction for lead optimization.
Keywords: COVID-19; Cytokine release syndrome; Interleukin 6; MD simulation; Protein–protein interactions.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Structure-based 3D-Pharmacophore modeling to discover novel interleukin 6 inhibitors: An in silico screening, molecular dynamics simulations and binding free energy calculations.PLoS One. 2022 Apr 6;17(4):e0266632. doi: 10.1371/journal.pone.0266632. eCollection 2022. PLoS One. 2022. PMID: 35385549 Free PMC article.
-
Identification of small molecules as potential inhibitors of interleukin 6: a multi-computational investigation.Mol Divers. 2023 Oct;27(5):2315-2330. doi: 10.1007/s11030-022-10558-7. Epub 2022 Nov 1. Mol Divers. 2023. PMID: 36319930 Free PMC article.
-
Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.Eur J Pharmacol. 2023 Oct 15;957:175961. doi: 10.1016/j.ejphar.2023.175961. Epub 2023 Aug 5. Eur J Pharmacol. 2023. PMID: 37549730
-
Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review).Exp Ther Med. 2021 Jan;21(1):24. doi: 10.3892/etm.2020.9456. Epub 2020 Nov 9. Exp Ther Med. 2021. PMID: 33262810 Free PMC article. Review.
-
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.Heliyon. 2021 Feb;7(2):e06158. doi: 10.1016/j.heliyon.2021.e06158. Epub 2021 Jan 29. Heliyon. 2021. PMID: 33553708 Free PMC article. Review.
References
-
- Fajgenbaum DC, June CH (2020) Cytokine storm. N Engl J Med 383:2255–2273. https://doi.org/10.1056/NEJMra2026131 - DOI - PubMed - PMC
-
- Shimabukuro-Vornhagen A, Gödel P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https://doi.org/10.1186/s40425-018-0343-9 - DOI - PubMed - PMC
-
- Fagan N, Meah N, York K et al (2021) Shedding light on therapeutics in alopecia and their relevance to COVID-19. Clin Dermatol 39:76–83. https://doi.org/10.1016/j.clindermatol.2020.12.015 - DOI - PubMed
-
- Hojyo S, Uchida M, Tanaka K et al (2020) How COVID-19 induces cytokine storm with high mortality. Inflamm Regener 40:37. https://doi.org/10.1186/s41232-020-00146-3 - DOI
-
- Wang C, Xie J, Zhao L et al (2020) Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients. eBioMedicine 57:e102833. https://doi.org/10.1016/j.ebiom.2020.102833 - DOI
LinkOut - more resources
Full Text Sources
Miscellaneous